PURPOSE: Activation of the apoptotic cascade plays an important role in the response of tumors to therapy. Noninvasive imaging of apoptosis facilitates optimization of therapeutic protocols regarding dosing and schedule and enables identification of efficacious combination therapies. EXPERIMENTAL DESIGN: We describe a hybrid polypeptide that reports on caspase-3 activity in living cells and animals in a noninvasive manner. This reporter, ANLucBCLuc, constitutes a fusion of small interacting peptides, peptide A and peptide B, with the NLuc and CLuc fragments of luciferase with a caspase-3 cleavage site (DEVD) between pepANLuc (ANLuc) and pepBCLuc (BCLuc). During apoptosis, caspase-3 cleaves the reporter, enabling separation of ANLuc from BCLuc. A high-affinity interaction between peptide A and peptide B restores luciferase activity by NLuc and CLuc complementation. Using a D54 glioma model, we show the utility of the reporter in imaging of apoptosis in living subjects in response to various chemotherapy and radiotherapy regimens. RESULTS: Treatment of live cells and mice carrying D54 tumor xenografts with chemotherapeutic agents such as temozolomide and perifosine resulted in induction of bioluminescence activity, which correlated with activation of caspase-3. Treatment of mice with combination therapy of temozolomide and radiation resulted in increased bioluminescence activity over individual treatments and increased therapeutic response due to enhanced apoptosis. CONCLUSION: The data provided show the utility of the ANLucBCLuc reporter in dynamic, noninvasive imaging of apoptosis and provides a rationale for use of this technology to optimize dose and schedule of novel therapies or to develop novel combination therapies using existing drugs.
PURPOSE: Activation of the apoptotic cascade plays an important role in the response of tumors to therapy. Noninvasive imaging of apoptosis facilitates optimization of therapeutic protocols regarding dosing and schedule and enables identification of efficacious combination therapies. EXPERIMENTAL DESIGN: We describe a hybrid polypeptide that reports on caspase-3 activity in living cells and animals in a noninvasive manner. This reporter, ANLucBCLuc, constitutes a fusion of small interacting peptides, peptide A and peptide B, with the NLuc and CLuc fragments of luciferase with a caspase-3 cleavage site (DEVD) between pepANLuc (ANLuc) and pepBCLuc (BCLuc). During apoptosis, caspase-3 cleaves the reporter, enabling separation of ANLuc from BCLuc. A high-affinity interaction between peptide A and peptide B restores luciferase activity by NLuc and CLuc complementation. Using a D54 glioma model, we show the utility of the reporter in imaging of apoptosis in living subjects in response to various chemotherapy and radiotherapy regimens. RESULTS: Treatment of live cells and mice carrying D54 tumor xenografts with chemotherapeutic agents such as temozolomide and perifosine resulted in induction of bioluminescence activity, which correlated with activation of caspase-3. Treatment of mice with combination therapy of temozolomide and radiation resulted in increased bioluminescence activity over individual treatments and increased therapeutic response due to enhanced apoptosis. CONCLUSION: The data provided show the utility of the ANLucBCLuc reporter in dynamic, noninvasive imaging of apoptosis and provides a rationale for use of this technology to optimize dose and schedule of novel therapies or to develop novel combination therapies using existing drugs.
Authors: A Seluanov; V Gorbunova; A Falcovitz; A Sigal; M Milyavsky; I Zurer; G Shohat; N Goldfinger; V Rotter Journal: Mol Cell Biol Date: 2001-03 Impact factor: 4.272
Authors: Bharathi Laxman; Daniel E Hall; Mahaveer Swaroop Bhojani; Daniel A Hamstra; Thomas L Chenevert; Brian D Ross; Alnawaz Rehemtulla Journal: Proc Natl Acad Sci U S A Date: 2002-12-10 Impact factor: 11.205
Authors: J van Rijn; J J Heimans; J van den Berg; P van der Valk; B J Slotman Journal: Int J Radiat Oncol Biol Phys Date: 2000-06-01 Impact factor: 7.038
Authors: Julia M Coppola; Christin A Hamilton; Mahaveer S Bhojani; Martha J Larsen; Brian D Ross; Alnawaz Rehemtulla Journal: Anal Biochem Date: 2007-01-17 Impact factor: 3.365
Authors: Dora B Bocangel; Sydney Finkelstein; S Clifford Schold; Kishor K Bhakat; Sankar Mitra; Demetrius M Kokkinakis Journal: Clin Cancer Res Date: 2002-08 Impact factor: 12.531
Authors: M Crul; H Rosing; G J de Klerk; R Dubbelman; M Traiser; S Reichert; N G Knebel; J H M Schellens; J H Beijnen; W W ten Bokkel Huinink Journal: Eur J Cancer Date: 2002-08 Impact factor: 9.162
Authors: Mahaveer S Bhojani; Mukesh K Nyati; Lili Zhao; Daniel P Normolle; Brian D Ross; Theodore S Lawrence; Alnawaz Rehemtulla Journal: Transl Oncol Date: 2011-06-01 Impact factor: 4.243
Authors: Craig J Galbán; Stefanie Galbán; Marcian E Van Dort; Gary D Luker; Mahaveer S Bhojani; Alnawaz Rehemtulla; Brian D Ross Journal: Prog Mol Biol Transl Sci Date: 2010 Impact factor: 3.622
Authors: Marcin Poreba; Aleksandra Szalek; Paulina Kasperkiewicz; Wioletta Rut; Guy S Salvesen; Marcin Drag Journal: Chem Rev Date: 2015-11-09 Impact factor: 60.622
Authors: Hanxiao Wang; Stefanie Galbán; Rong Wu; Brittany M Bowman; Amanda Witte; Katrin Vetter; Craig J Galbán; Brian D Ross; Kathleen R Cho; Alnawaz Rehemtulla Journal: Clin Cancer Res Date: 2012-10-24 Impact factor: 12.531
Authors: Wei Yang; Sarah R Hosford; Lloye M Dillon; Kevin Shee; Stephanie C Liu; Jennifer R Bean; Laurent Salphati; Jodie Pang; Xiaolin Zhang; Michelle A Nannini; Eugene Demidenko; Darcy Bates; Lionel D Lewis; Jonathan D Marotti; Alan R Eastman; Todd W Miller Journal: Clin Cancer Res Date: 2016-01-05 Impact factor: 12.531